| Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives L Urso, A Castello, GC Rocca, F Lancia, S Panareo, C Cittanti, L Uccelli, ... Journal of Cancer Research and Clinical Oncology 148 (6), 1299-1311, 2022 | 28 | 2022 |
| 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans L Uccelli, A Boschi, C Cittanti, P Martini, S Panareo, E Tonini, A Nieri, ... Pharmaceutics 13 (9), 1463, 2021 | 27 | 2021 |
| PET-derived radiomics and artificial intelligence in breast cancer: a systematic review L Urso, L Manco, A Castello, L Evangelista, G Guidi, M Castellani, ... International Journal of Molecular Sciences 23 (21), 13409, 2022 | 26 | 2022 |
| 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study G Paganelli, M Sansovini, S Nicolini, I Grassi, T Ibrahim, E Amadori, ... European journal of nuclear medicine and molecular imaging 48, 152-160, 2021 | 25 | 2021 |
| Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study A Cistaro, N Quartuccio, MC Garganese, MF Villani, C Altini, M Pizzoferro, ... European Journal of Nuclear Medicine and Molecular Imaging, 1-12, 2022 | 17 | 2022 |
| The role of radiomics in the era of immune checkpoint inhibitors: a new protagonist in the jungle of response criteria A Castello, M Castellani, L Florimonte, L Urso, L Mansi, E Lopci Journal of Clinical Medicine 11 (6), 1740, 2022 | 15 | 2022 |
| Fdg pet/ct volume-based quantitative data and survival analysis in breast cancer patients: A systematic review of the literature L Evangelista, L Urso, M Caracciolo, F Stracuzzi, S Panareo, A Cistaro, ... Current medical imaging 19 (8), 807-816, 2023 | 13 | 2023 |
| The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review M Caracciolo, A Castello, L Urso, F Borgia, N Ortolan, L Uccelli, C Cittanti, ... Cancers 14 (20), 5036, 2022 | 12 | 2022 |
| Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach L Filippi, L Urso, F Bianconi, B Palumbo, MC Marzola, L Evangelista, ... Expert Review of Molecular Diagnostics 23 (3), 243-255, 2023 | 10 | 2023 |
| 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? L Urso, F Lancia, N Ortolan, M Frapoli, M Rauso, P Artioli, C Cittanti, ... Clinical and Translational Imaging 10 (6), 687-695, 2022 | 10 | 2022 |
| Rhenium radioisotopes for medicine, a focus on production and applications L Uccelli, P Martini, L Urso, T Ghirardi, L Marvelli, C Cittanti, A Carnevale, ... Molecules 27 (16), 5283, 2022 | 10 | 2022 |
| Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE L Urso, A Nieri, L Uccelli, A Castello, P Artioli, C Cittanti, MC Marzola, ... Pharmaceutics 15 (4), 1110, 2023 | 9 | 2023 |
| Clinical applications of long axial field-of-view PET/CT scanners in oncology L Urso, V Frantellizzi, G De Vincentis, O Schillaci, L Filippi, L Evangelista Clinical and Translational Imaging 11 (4), 365-380, 2023 | 8 | 2023 |
| Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective … L Urso, S Panareo, A Castello, MR Ambrosio, MC Zatelli, M Caracciolo, ... Pharmaceutics 14 (10), 2009, 2022 | 8 | 2022 |
| Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer L Urso, N Quartuccio, M Caracciolo, L Evangelista, A Schirone, ... Nuclear Medicine Communications 43 (2), 212-219, 2022 | 8 | 2022 |
| Oldie but goodie: Is technetium-99m still a treasure trove of innovation for medicine? A Patents Analysis (2000–2022) M Riondato, D Rigamonti, P Martini, C Cittanti, A Boschi, L Urso, L Uccelli Journal of Medicinal Chemistry 66 (7), 4532-4547, 2023 | 7 | 2023 |
| The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with … L Urso, L Evangelista, P Alongi, N Quartuccio, C Cittanti, I Rambaldi, ... Cancers 14 (23), 5869, 2022 | 7 | 2022 |
| Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: A literature review L Urso, A Nieri, I Rambaldi, A Castello, L Uccelli, C Cittanti, S Panareo, ... Endocrine 78 (2), 255-261, 2022 | 7 | 2022 |
| PET criteria by cancer type from imaging interpretation to treatment response assessment: beyond FDG PET score F Dondi, A Lazzarato, J Gorica, P Guglielmo, F Borgia, R Filice, A Vento, ... Life 13 (3), 611, 2023 | 6 | 2023 |
| ITA-IMMUNO-PET: the role of [18F] FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors L Evangelista, A Bianchi, A Annovazzi, R Sciuto, S Di Traglia, ... Cancers 15 (3), 878, 2023 | 6 | 2023 |
